IndusInd Bank

After some speculation regarding IndusInd Bank, the Reserve Bank of India stated that the bank is well-capitalized, and its financial position remains satisfactory. As per the financial results for Q3FY25, the bank has maintained a comfortable capital adequacy ratio of 16.46% and a provision coverage ratio of 70.20%. The liquidity coverage ratio stood at 113% as of March 9, against the regulatory requirement of 100%. IndusInd Bank has already engaged an external audit team to comprehensively review its current systems and assess the actual impact expeditiously.
Therefore, there is no need for depositors to react to the speculative reports at this juncture, as the bank’s financial health remains stable and is being closely monitored by the Reserve Bank. Meanwhile, HDFC Mutual Fund acquired a 0.2% stake on March 11, increasing its shareholding to 5.02%, from 4.82% earlier.

KEC International

The infrastructure EPC major has received new orders worth Rs 1,267 crore in the transmission & distribution and cable businesses. With these new orders, its YTD order intake stands at over Rs 23,300 crore, a growth of 35% compared to the same period last year.

Welspun Specialty Solutions

Bharat Heavy Electricals (BHEL) has awarded a formal purchase contract worth Rs 231.78 crore to the company. The contract is expected to be executed progressively over the next 13 months (by April 2026). Earlier, on March 4, BHEL (Trichy) had selected Welspun Specialty Solutions as the L1 bidder for the supply of 4,050 tons of stainless steel seamless boiler tubes for a series of super-critical thermal power projects.

Alkem Laboratories

The US FDA conducted a Bioresearch Monitoring (BIMO) inspection at the company’s Bioequivalence Center in Taloja, Maharashtra, during March 10-13. At the end of the inspection, no Form 483 was issued by the US FDA. Additionally, the company's subsidiary, Alkem Medtech, has executed a Share Purchase and Share Subscription Agreement with Bombay Ortho Industries to acquire 100% stake in Bombay Ortho.

Shilpa Medicare

The United States Food and Drug Administration (USFDA) has conducted an inspection at Unit-2 of Shilpa Pharma Lifesciences, located in Raichur, during March 10-14. The US FDA closed the inspection with zero observations. This is the second consecutive zero 483 inspection at this site. Shilpa Pharma Lifesciences is a wholly owned subsidiary of Shilpa Medicare.

GR Infraprojects

The company has emerged as the selected bidder by the National Highways Authority of India for a project worth Rs 4,262.78 crore. The project involves the construction of the Agra-Gwalior greenfield road across Uttar Pradesh, Rajasthan, and Madhya Pradesh.

Maharashtra Seamless

The company has received an order worth Rs 298 crore for the supply of seamless pipes for the oil & gas sector.

Dr Reddy’s Laboratories

The pharma company is recalling one batch of Levetiracetam in 0.75% sodium chloride injection single-dose infusion bags in the United States due to incorrect labeling of the infusion bag. According to the risk statement, patients administered the mislabeled product are likely to experience adverse events.

Tata Motors

The company announced its intention to appoint Deloitte Haskins & Sells LLP as statutory auditors, effective FY28, subject to the completion of all regulatory compliances. BSR & Co LLP, the current statutory auditors, will continue to audit Tata Motors until FY27.

Voltas

The Board has appointed K V Sridhar as the Chief Financial Officer of the company, effective April 1, 2025, upon the superannuation of Jitender Pal Verma. Additionally, the Board has approved the transfer of overseas branches in Dubai and Abu Dhabi to the company’s subsidiary, Universal MEP Contracting LLC, Dubai, UAE, for Rs 45-70 crore.

Brigade Enterprises

The company has launched its residential project – Ebony at Brigade Orchards in Devanahalli, with a revenue potential of over Rs 380 crore, and another residential project – Brigade Eternia in Yelahanka, with a revenue potential of over Rs 2,700 crore.

Tejas Networks

The company has received Rs 123.45 crore from the Department of Telecommunications as an incentive for FY24 under the PLI (Production Linked Incentive) scheme for telecom and networking products.

KPIT Technologies

Qualcomm Ventures LLC is set to acquire a shareholding worth up to 10 million euros in the Qorix GmbH joint venture. Qualcomm will be the third shareholder in Qorix GmbH, alongside KPIT and ZF.

Galaxy Surfactants

The Board has approved and declared an interim dividend of Rs 18 per equity share for FY25. The record date for the payment of this interim dividend is set as March 20.

Patanjali Foods

Adar Poonawalla-owned Sanoti Properties has decided to sell its stake in its insurance subsidiary, Magma General Insurance, to Baba Ramdev's Patanjali Ayurved and DS Group, for Rs 4,500 crore. Patanjali Ayurved is one of the promoters of Patanjali Foods.

NTC Industries

The company has withdrawn its proposal for the acquisition of a 51% equity stake in Solitude Flame, leading to the termination of the share swap agreement. The termination of this proposal will not have any material adverse financial or operational impact on the company.

3M India

The Board has appointed Nikhil Arora as Chief Financial Officer of the company, effective May 5, and Jayanand Vasudeorao Kaginalkar as an Additional Director of the company, categorized as Executive Director, effective April 1.

International Conveyors

The company has acquired 27,228 equity shares worth Rs 2.95 crore in Central Depository Services, and 1,29,685 equity shares worth Rs 2.65 crore in La Opala RG for investment purposes.

Ksolves India

The Board will meet on March 19 to declare the third interim dividend for FY25. The record date for the dividend, if declared, will be March 25.

Zydus Lifesciences

The company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Eluxadoline tablets, which are available in 75 mg and 100 mg strengths. Eluxadoline is a mu-opioid receptor agonist indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

Vikasdhan - Grow your Dhan with Vikasdhan

Disclaimer- not an investment advice, only for educational purpose. Read full disclaimer https://vikasdhan.com/disclaimer